Role of proteasome inhibition in sensitized transplant candidates

Chinese Medical Journal

Volumn 124, Issue 5, 2011, Pages 771-774

  Everly, Matthew J ^a   Everly, Jason J ^a   Terasaki, Paul I ^a  

^a One Lambda Inc   (United States)

Author keywords

Alloantibodies; Bortezomib; Desensitization; Human leukocyte antigen; Plasma cell; Proteasome inhibition; Transplantation

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN G; PROTEASOME; RITUXIMAB;

ANEMIA; ANTIBODY PRODUCTION; CARDIAC GRAFT REJECTION; DESENSITIZATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; HUMAN; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; LUNG GRAFT REJECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; PLASMAPHERESIS; PROTEIN DEGRADATION; REVIEW; THROMBOCYTOPENIA; VOMITING;

BORONIC ACIDS; GRAFT REJECTION; HUMANS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TRANSPLANTS;

EID: 79952493808     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.05.025     Document Type: Review

References (29)

1. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. In: U.S. Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation. Rockville; 2008.
2. Cecka JM. Kidney transplantation in the United States. Clin Transpl 2008: 1-18.
3. Terasaki PI, Kreisler M, Mickey RM. Presensitization and kidney transplant failures. Postgrad Med J 1971; 47: 89-100.
4. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
5. Cook DJ, Terasaki PI, Iwaki Y, Terashita G, Takeda A, Fujikawa J, et al. The flow cytometry crossmatch in kidney transplantation. Clin Transpl 1987: 409-414.
6. Ogura K, Terasaki PI, Johnson C, Mendez R, Rosenthal JT, Ettenger R, et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993; 56: 294-298.
7. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500.
8. Mizutani K. HLA mismatches and PRA in kidney retransplants. Clin Transpl 2007: 19-27.
9. Dean PG, Gloor JM, Stegall MD. Conquering absolute contraindications to transplantation: positive-crossmatch and ABO-incompatible kidney transplantation. Surgery 2005; 137: 269-273.
10. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
11. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
12. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21: 30-36.
13. Everly JJ, Walsh RC, Alloway RR, Woodle ES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
14. Wu J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002; 2: 904-912.
15. Everly MJ, Terasaki PI, Trivedi HL, Kaneku H, Idica A. DSA monitoring may improve donor specific HLA-antibody relapse and refratoriness following proteasome inhibition. Am J Transplant 2010; 10 (Suppl 4): 467.
16. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
17. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
18. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
19. Everly MJ, Terasaki PI, Trivedi HL, Deng C, Hopfield J, Kaneku H, et al. Proteasome inhibition spares protective immunity while removing donor specific HLA antibodies. Am J Transplant 2010; 10 (Suppl 4): 146.
20. Neumann J, Schio S, Tarrasconi H, Bortolotto A, Costa C, Machuca T, et al. Bortezomib in lung transplantation: a promising start. Clin Transpl 2009: 421-424.
21. Raghavaiah SR, Daiwan TS, Burns JM, Gloor JM, Gandhi MJ, Winters JL, et al. Depletion of alloantibody-secreting plasma cells by proteasome inhibition improves desensitization. Am J Transplant 2010; 10 (Suppl 4): 44.
22. Walsh RC, Rike Shields A, Wall GE, Brailey P, Girnita A, Cardi M, et al. A prospective, staged trial of proteasome inhibitor-based therapy for reduction of HLA sensitization in kidney transplant candidates. Am J Transplant 2010; 10 (Suppl 4): 44.
23. Wahrmann M, Haidinger M, Kormoczi GF, Weichhart T, Saemann MD, Geyeregger R, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385-1390
24. Lonze BE, Dagher NN, Simpkins CE, Singer AL, Segev DL, Zachary AA, et al. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib. Clin Transpl 2009: 377-384.
25. Patel JK, Everly MJ, Kittleson M, Kobashigawa JA. Use of bortezomib as adjunctive therapy for desensitization in combined heart and kidney transplantation: a case report. Clin Transpl 2009: 347-349.
26. Raghavan R, Jeroudi A, Achkar K, Suki W, Gaber AO, Knight R, et al. Bortezomib in kidney transplant desensitization: a case report. Clin Transpl 2009: 339-341.
27. Wahrmann M, Haidinger M, Drach J, Geyeregger R, Kikic Z, Raab H, et al. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment. Clin Transpl 2009: 415-420.
28. Weston M, Rolfe M, Haddad T, Lopez-Cepero M. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants. Clin Transpl 2009: 393-399.
29. Zhu L, Lin Z, Xiang Y, Liu S, Chen G. Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol. Clin Transpl 2009: 359-360.